Literature DB >> 17505471

Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence.

Julien Marquis1, Kathrin Meyer, Larissa Angehrn, Sacha S Kämpfer, Barbara Rothen-Rutishauser, Daniel Schümperli.   

Abstract

Spinal muscular atrophy (SMA) is a lethal hereditary disease caused by homozygous deletion/inactivation of the survival of motoneuron 1 (SMN1) gene. The nearby SMN2 gene, despite its identical coding capacity, is only an incomplete substitute, because a single nucleotide difference impairs the inclusion of its seventh exon in the messenger RNA (mRNA). This splicing defect can be corrected (transiently) by specially designed oligonucleotides. Here we have developed a more permanent correction strategy based on bifunctional U7 small nuclear RNAs (snRNAs). These carry both an antisense sequence that allows specific binding to exon 7 and a splicing enhancer sequence that will improve the recognition of the targeted exon. When expression cassettes for these RNAs are stably introduced into cells, the U7 snRNAs become incorporated into small nuclear ribonucleoprotein (snRNP) particles that will induce a durable splicing correction. We have optimized this strategy to the point that virtually all SMN2 pre-mRNA becomes correctly spliced. In fibroblasts from an SMA patient, this approach induces a prolonged restoration of SMN protein and ensures its correct localization to discrete nuclear foci (gems).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17505471     DOI: 10.1038/sj.mt.6300200

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  37 in total

Review 1.  Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy.

Authors:  Sebastian Lunke; Assam El-Osta
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

2.  DHPR alpha1S subunit controls skeletal muscle mass and morphogenesis.

Authors:  France Piétri-Rouxel; Christel Gentil; Stéphane Vassilopoulos; Dominique Baas; Etienne Mouisel; Arnaud Ferry; Alban Vignaud; Christophe Hourdé; Isabelle Marty; Laurent Schaeffer; Thomas Voit; Luis Garcia
Journal:  EMBO J       Date:  2009-12-24       Impact factor: 11.598

3.  Antisense oligonucleotides and spinal muscular atrophy: skipping along.

Authors:  Arthur H M Burghes; Vicki L McGovern
Journal:  Genes Dev       Date:  2010-08-01       Impact factor: 11.361

Review 4.  Repair of pre-mRNA splicing: prospects for a therapy for spinal muscular atrophy.

Authors:  Rachel Nlend Nlend; Kathrin Meyer; Daniel Schümperli
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

Review 5.  Spinal muscular atrophy: mechanisms and therapeutic strategies.

Authors:  Christian L Lorson; Hansjorg Rindt; Monir Shababi
Journal:  Hum Mol Genet       Date:  2010-04-13       Impact factor: 6.150

6.  Correct mRNA processing at a mutant TT splice donor in FANCC ameliorates the clinical phenotype in patients and is enhanced by delivery of suppressor U1 snRNAs.

Authors:  Linda Hartmann; Kornelia Neveling; Stephanie Borkens; Hildegard Schneider; Marcel Freund; Elke Grassman; Stephan Theiss; Angela Wawer; Stefan Burdach; Arleen D Auerbach; Detlev Schindler; Helmut Hanenberg; Heiner Schaal
Journal:  Am J Hum Genet       Date:  2010-10-08       Impact factor: 11.025

Review 7.  Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.

Authors:  Natalia N Singh; Brian M Lee; Christine J DiDonato; Ravindra N Singh
Journal:  Future Med Chem       Date:  2015-09-18       Impact factor: 3.808

8.  Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy.

Authors:  Tristan H Coady; Christian L Lorson
Journal:  J Neurosci       Date:  2010-01-06       Impact factor: 6.167

Review 9.  SMN-inducing compounds for the treatment of spinal muscular atrophy.

Authors:  Monique A Lorson; Christian L Lorson
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

10.  Functional correction by antisense therapy of a splicing mutation in the GALT gene.

Authors:  Ana I Coelho; Sílvia Lourenço; Matilde Trabuco; Maria João Silva; Anabela Oliveira; Ana Gaspar; Luísa Diogo; Isabel Tavares de Almeida; João B Vicente; Isabel Rivera
Journal:  Eur J Hum Genet       Date:  2014-07-23       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.